Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study

AIMS: Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso‐enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug–drug interaction may occur. I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Clin Pharmacol
Auteurs principaux: Belderbos, Bodine P.S., Hussaarts, Koen G.A.M., van Harten, Leonie J., Oomen‐de Hoop, Esther, de Bruijn, Peter, Hamberg, Paul, van Alphen, Robbert J., Haberkorn, Brigitte C.M., Lolkema, Martijn P., de Wit, Ronald, van Soest, Robert J., Mathijssen, Ron H.J.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6475678/
https://ncbi.nlm.nih.gov/pubmed/30737835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13889
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires